Adiponectin and HIV-lipodystrophy: taking HAART.
Kinlaw
William B
WB
Division of Endocrinology, and Norris Cotton Cancer Center, Dartmouth Medical School, 606 Rubin Building, 1 Medical Center Drive, Lebanon, New Hampshire 03756, USA. William.kinlaw@hitchcock.org
Marsh
Bryan
B
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy*; D052242:Adiponectin; D000818:Animals; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D022762:CCAAT-Enhancer-Binding Proteins; D002318:Cardiovascular Diseases / Q000139:chemically induced; D004268:DNA-Binding Proteins; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced*; D006801:Humans; D007333:Insulin Resistance; D036341:Intercellular Signaling Peptides and Proteins; D051379:Mice; D011506:Proteins / Q000502:physiology*; D051780:Sterol Regulatory Element Binding Protein 1; D014157:Transcription Factors
D052242:Adiponectin; D022762:CCAAT-Enhancer-Binding Proteins; D004268:DNA-Binding Proteins; D036341:Intercellular Signaling Peptides and Proteins; D011506:Proteins; C497387:SREBF1 protein, human; C497388:Srebf1 protein, mouse; D051780:Sterol Regulatory Element Binding Protein 1; D014157:Transcription Factors